GLAUKOS Corp (GKOS) stock
GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 7/30219% above fair value
$245.72−0.31 (-0.13%)
Close on Nov 13, 2026Market cap $14.55BP/E –Yield –
Glaukos EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Glaukos's EPS for the twelve months ending Sep 30, 2026 was -$2.94. For fiscal 2025 it was -$3.28. The highest annual figure on record is $0.37 in fiscal 2019.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.28 | – |
| FY2024 | Dec 31, 2024 | -$2.77 | – |
| FY2023 | Dec 31, 2023 | -$2.78 | – |
| FY2022 | Dec 31, 2022 | -$2.09 | – |
| FY2021 | Dec 31, 2021 | -$1.07 | – |
| FY2020 | Dec 31, 2020 | -$2.70 | -829.7% |
| FY2019 | Dec 31, 2019 | $0.37 | – |
| FY2018 | Dec 31, 2018 | -$0.37 | – |
| FY2017 | Dec 31, 2017 | $0.00 | -100.0% |
| FY2016 | Dec 31, 2016 | $0.12 | – |
| FY2015 | Dec 31, 2015 | -$2.13 | – |
| FY2014 | Dec 31, 2014 | -$5.29 | – |
| FY2013 | Dec 31, 2013 | -$6.21 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.03 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.31 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.34 | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.32 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.28 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.34 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.32 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.60 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.39 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.00 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.82 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.75 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.63 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.72 | -754.5% |
| Q4 FY2022 | Dec 31, 2022 | -$0.66 | -240.4% |
| Q3 FY2022 | Sep 30, 2022 | -$0.58 | -546.2% |
| Q2 FY2022 | Jun 30, 2022 | -$0.96 | – |
| Q1 FY2022 | Mar 31, 2022 | $0.11 | – |
| Q4 FY2021 | Dec 31, 2021 | $0.47 | – |
| Q3 FY2021 | Sep 30, 2021 | $0.13 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.38 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.36 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.24 | -128.6% |
| Q3 FY2020 | Sep 30, 2020 | -$0.35 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.90 | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.24 | – |
| Q4 FY2019 | Dec 31, 2019 | $0.84 | +2000.0% |
| Q3 FY2019 | Sep 30, 2019 | -$0.37 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.17 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.04 | – |
| Q4 FY2018 | Dec 31, 2018 | $0.04 | +33.3% |
| Q3 FY2018 | Sep 30, 2018 | -$0.19 | -575.0% |
| Q2 FY2018 | Jun 30, 2018 | -$0.15 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.08 | -500.0% |
| Q4 FY2017 | Dec 31, 2017 | $0.03 | – |
| Q3 FY2017 | Sep 30, 2017 | $0.04 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.10 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.02 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?